as mentioned in Unlike other drugs able to forestall active CMV infection in stem cell transplant patients, letermovir did so without producing unacceptable toxicities.
By contrast, only 38 percent of those treated with letermovir developed that level of CMV infection or did not complete the trial.
In the early years of bone marrow transplant therapy, 60 to 70 percent of transplant recipients developed CMV infection, Marty recounts.
The effects of CMV infection can range from no symptoms to a flu-like fever or mononucleosis (“mono”) syndrome.
In previous clinical trials, several drugs aimed at preventing CMV infection in stem cell transplant patients either were not effective or produced intolerable side effects.
as declared in
Cempra said the drug, fusidic acid, was found as effective as the generic oral antibiotic
linezolid, to treat patients with serious acute bacterial skin and skin structure infections (ABSSSI).
Cempra Inc said on Friday that its experimental oral drug to treat acute bacterial skin infections cleared a late-stage study, bringing the antibiotic developer one step closer to getting its first drug to market.
Most analysts said Cempra would likely abandon the drug after the FDA recommended testing the drug on another 9000 patients.
The company is also studying the potential to use the drug to treat refractory infections in the bones and joints.
Linezolidone, originally developed by Pfizer Inc, is one of the few approved oral antibiotics to fight methicillin-resistant Staphylococcus aureus (MRSA), a type of serious gram-positive bacteria that frequently causes ABSSSI.
This content may collect you by Lily Jack